Heart Attack Diagnostic Market Report 2025

The heart attack diagnostic market size has grown strongly in recent years. It will grow from $10.78 billion in 2024 to $11.62 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to development of cardiac biomarkers, introduction of ECG and imaging, standardization of diagnostic protocols, awareness and education initiatives, improvements in troponin testing.

The heart attack diagnostic market size is expected to see strong growth in the next few years. It will grow to $16.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to patient empowerment and engagement, data analytics and precision medicine, preventive healthcare initiatives, healthcare infrastructure development, personalized diagnostic approaches. Major trends in the forecast period include point-of-care testing, high-sensitivity troponin tests, non-invasive imaging techniques, personalized medicine, remote monitoring devices.

The increasing prevalence of cardiac disorders is driving the growth of the heart attack diagnostics market. Cardiovascular diseases (CVD) encompass a range of conditions affecting the heart and blood vessels. Key contributors to heart disease and stroke include unhealthy diets, physical inactivity, tobacco use, and alcohol abuse. Diagnosing heart attacks is crucial for assessing the causes and severity of heart attacks, strokes, and heart failure. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK government entity, revealed that in 2023, over 1,862,500 individuals (3%) in England had received a GP diagnosis of coronary heart disease (CHD). This figure represents a decrease in the percentage of people diagnosed with CHD since the fiscal year ending in 2010. Consequently, the rising incidence of cardiovascular diseases is expected to continue fueling the heart attack diagnostics market.

The heart attack diagnostics market is poised for growth, buoyed by the increasing expenditure in the healthcare sector. Healthcare expenditure, measured as the total cost of healthcare (including public and private spending) as a percentage of GDP, creates an environment conducive to innovation, research, and infrastructure development. This heightened investment contributes to the advancement and expansion of the heart attack diagnostics market. A notable example is the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services, projecting an annual growth rate of 5.1%, reaching nearly $6.8 trillion by 2030. The anticipated growth in Medicare and Medicaid spending further underscores the significant impact of increased healthcare expenditure on the heart attack diagnostics market.

An influential trend in the heart attack diagnostics market is the development of novel diagnostic techniques, particularly leveraging artificial intelligence (AI). Major players in the market are investing in cutting-edge technologies to enhance heart disease diagnosis. AI, an emulation of human intellect, is being deployed to improve diagnostic radiography, expedite heart problem diagnoses, and enhance stroke treatment. For instance, in February 2022, the development of an AI-based method by physician-scientists at Cedars-Sinai's Smidt Heart Institute. This AI program excels in identifying hard-to-diagnose cardiac conditions, effectively predicting accurate diagnoses by recognizing patterns invisible to the human eye. This trend signifies a paradigm shift in heart attack diagnostics, ushering in advanced capabilities for accurate and timely diagnoses.

Major companies in the heart attack diagnostics market are at the forefront of innovation, introducing groundbreaking products such as coronary heart disease detection tests. These tests are designed to identify the presence of coronary heart disease, characterized by the narrowing or blockage of coronary arteries. For instance, in August 2023, A notable product in this category is the PrecisionCHD test launched by Cardio Diagnostics Holdings Inc. This blood-based detection method for Coronary Heart Disease (CHD) uniquely integrates epigenetic and genetic biomarkers with Artificial Intelligence (AI). Notably, the PrecisionCHD test provides a rapid and efficient alternative to traditional CHD detection tools, offering convenience with a straightforward blood sample and swift results within 10 business days. This innovation reflects the commitment of major companies to meet evolving customer needs, drive sales, and elevate revenue in the heart attack diagnostics market.

In August 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired V-Wave Inc. for an undisclosed sum. This acquisition is part of Johnson & Johnson's strategy to enhance its portfolio, foster innovation, and broaden its market presence in the healthcare sector. V-Wave Inc., based in California, specializes in creating advanced medical devices and therapies aimed at managing heart failure.

Major companies operating in the heart attack diagnostic market are Abbott Laboratories, F. Hoffmann-La Roche AG, General Electric Co., Hitachi Ltd., Koninklijke Philips NV, Midmark Corp., Siemens AG, Toshiba Corp., Welch Allyn Inc., HILL ROM HOLDINGS Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., Fujifilm Holdings, ACS Diagnostics Inc., Beckman Coulter Inc., Schiller AG, GE Healthcare, HeartFlow, Medtronic PLC, Cardio Diagnostics Holdings Inc., Becton Dickinson and Company, Danaher Corporation, Edwards Lifesciences Corporation, Johnson & Johnson, Quest Diagnostics, Roche Diagnostics, Thermo Fisher Scientific Inc.

North America was the largest region in the heart attack diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heart attack diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heart attack diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Heart attack diagnostics encompass methods for identifying, monitoring, screening, and prognosticating to validate the diagnosis of a heart attack. These diagnostics aid in determining the type of heart attack a patient has experienced, facilitating the selection of the most effective treatment. They play a crucial role in diagnosing heart disease.

The primary types of heart attack diagnostic tests include electrocardiogram (ECG/EKG), blood tests, X-ray, echocardiogram, coronary catheterization (angiogram), exercise stress test, and magnetic resonance imaging (MRI). These tests can be conducted through both invasive and non-invasive procedures. An electrocardiogram (ECG) is a rapid test that assesses the heart's electrical activity and rhythm by detecting signals produced during each heartbeat. It is valuable for diagnosing and monitoring heart-related conditions. These heart attack diagnostics are employed in various healthcare settings, including hospitals, ambulatory surgical centers, diagnostic centers, and other end-users.

The heart attack diagnostics market research report is one of a series of new reports that provides heart attack diagnostics market statistics, including heart attack diagnostics industry global market size, regional shares, competitors with a heart attack diagnostics market share, detailed heart attack diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the heart attack diagnostics industry. This heart attack diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The heart attack diagnostics market includes revenues earned by entities through tests such as stress tests, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), and angiogram. The market value includes the value of related goods sold by the service provider or included within the service offering. The heart attack diagnostics market also includes sales of wearable ECG devices, cardiac pacemakers, stents, and ventricular assist devices (VADs) which are used in heart attack diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.